Vestal Point Capital, LP Ascendis Pharma A/S Transaction History
Vestal Point Capital, LP
- $1.34 Trillion
- Q2 2024
A detailed history of Vestal Point Capital, LP transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Vestal Point Capital, LP holds 750,000 shares of ASND stock, worth $112 Million. This represents 7.63% of its overall portfolio holdings.
Number of Shares
750,000
Previous 525,000
42.86%
Holding current value
$112 Million
Previous $79.4 Billion
28.88%
% of portfolio
7.63%
Previous 6.56%
Shares
3 transactions
Others Institutions Holding ASND
# of Institutions
223Shares Held
56.5MCall Options Held
142KPut Options Held
259K-
Ra Capital Management, L.P. Boston, MA10.1MShares$1.51 Billion20.78% of portfolio
-
Westfield Capital Management CO LP Boston, MA4.96MShares$741 Million3.41% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI4.3MShares$641 Million0.93% of portfolio
-
Avoro Capital Advisors LLC New York, NY4.2MShares$627 Million7.81% of portfolio
-
Janus Henderson Group PLC London, X03.92MShares$585 Million0.29% of portfolio
About Ascendis Pharma A/S
- Ticker ASND
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,810,200
- Market Cap $8.33B
- Description
- Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...